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Glioblastoma multiforme (GBM) is the most common and 
malignant primary brain tumor. The median survival time is 
14.6 months from time of diagnosis, in spite of aggressive 
surgery, radiation therapy and chemotherapy. Only 3 to 5% of 
patients survive more than three years. Recurrence of GBM is 
nearly universal, confers a dismal prognosis with a 6-months 
progression free survival (6M-PFS) rate of 15% to 21% and a 
median survival of 6.2 months. Advancements in the past 
decades have not significantly increased the overall survival 
of patients with this disease. GBM has been demonstrated 
NK-1 receptor system and Substance P can be used as a 
ligand for targeted therapy. Alpha emitter, like 213Bi offers 
the new potential for selective irradiation of tumors, with 
minimizing damage to adjacent tissue.  
Material and methods: 21 patients with primary recurrent 
glia tumor IV after standard therapy were included in the 
study during two years. Following intracavitary or 
intratumoral insertion of 1-2 catheter systems, patients were 
treated with 1–8 doses of 2 GBq 213Bi-DOTA-Substance P (213Bi-
SP) in intervals of 2 months. 68Ga-DOTA-Substance P (68Ga-SP) 
was co-injected with the therapeutic doses to assess 
biodistribution using PET/CT. Therapeutic response was 
monitored with MRI. Study was approved by the ethical 
committee of the Medical University of Warsaw. 
Results: Treatment with activity up to 13 GBq 213Bi-SP was 
tolerated well with only mild transient adverse reactions: in 
1 patient transient increase of focal neurological symptoms 
and in 3 patients episodes of epileptic seizures several days 
after treatment. PET/CT imaging showed high retention of 
the radiolabeled peptide at the tumor site.  
Out of 21 evaluable patients, 17 progressed within the 
follow-up period, 5 of them are alive at the end of follow-up. 
Four patients were excluded from evaluation due to lack of 
data. Median progression free survival was 3.7 months, with a 
6 months progression free survival rate of 19% . The median 
overall survival from the first diagnosis was 25.2 months, and 
from the start of 213Bi-SP was 6.5 months. Follow up of 
therapeutic responses and toxicity is continued and patient 
recruitment is ongoing. Busk 
 
Conclusions: Treatment of recurrent GBM with 213Bi-SP is safe 
and well tolerated. Targeted alpha therapy with 213Bi-SP may 
evolve as a promising novel option for treatment of recurrent 
GBM. 
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A high-resolution silicon detector probe, in coincidence with 
a conventional  
PET scanner, is expected to provide images of higher spatial 
resolution than those achievable using the scanner alone, due 
to the finer pixelization of the probe detector[1]. A PET-
probe prototype is being developed utilizing this principle 
[2]. The system includes a probe consisting of ten layers of 
silicon detectors, each a 80×52 array of 1×1×1 mm3 pixels, to 
be operated in coincidence with a modern clinical PET 
scanner. Detailed simulation studies of this system have been 
performed to assess the effect of the additional probe 
information on the quality of the reconstructed images.  
Using the Monte-Carlo simulation package GATE, a grid of 
point sources was simulated to study the contribution of the 
probe to the system resolution at different locations over the 
field of view (FOV). A resolution phantom was used to 
demonstrate the effect on image resolution for two probe 
positions. A homogeneous source distribution with hot and 
cold regions was used to demonstrate that the localized 
improvement in resolution does not come at the expense of 
the overall quality of the image. An imaging study using 
experimental probe data was also performed. The list-mode 
maximum likelihood–expectation maximization (ML–EM) 
algorithm[3] was used for image reconstruction in all cases.  
As expected, the point spread function of the PET-probe 
system was found to be non-isotropic and vary with position, 
offering improvement in specific regions. An increase in 
resolution, of factors of up to 2, was observed in the region 
close to the probe. Images of the resolution phantom showed 
visible enhancement in resolution when including the probe 
in the simulations, as can be seen in figure 1. The image 
quality study demonstrated that contrast and spill-over ratio 
in other areas of the FOV were not sacrificed for this 
enhancement. The improvement in resolution when using the 
Si detector probe was also observed using the experimental 
prototype. In this context, previously unrecoverable features 
in a resolution phantom could be resolved when probe data 
was included during image reconstruction. Remaining 
challenges in developing the PET-probe system include 
overcoming the limitations imposed by the timing 
performance of the Si detectors and more detailed system 
modeling in image reconstruction.    
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Figure 1: Images of the resolution phantom reconstructed 
using data from the probe and from the scanner alone. The 
probe is located to the right of the image, in close proximity 
to the phantom.  The phantom features are 4.8, 4.0, 3.2, 2.4, 
1.6 and 1.2 mm in diameter. Pixels are 1 × 1 × 1 mm3 
